Your browser doesn't support javascript.
loading
Purity determination of amphotericin B, colistin sulfate and tobramycin sulfate in a hydrophilic suspension by HPLC.
Pfeifer, Corina; Fassauer, Georg; Gerecke, Hagen; Jira, Thomas; Remane, Yvonne; Frontini, Roberto; Byrne, Jonathan; Reinhardt, Robert.
Afiliação
  • Pfeifer C; Development Dept., mibe GmbH Arzneimittel, 06796 Brehna, Germany. Electronic address: corina.pfeifer@mibegmbh.de.
  • Fassauer G; Institute of Pharmacy, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany.
  • Gerecke H; Development Dept., mibe GmbH Arzneimittel, 06796 Brehna, Germany.
  • Jira T; Institute of Pharmacy, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany.
  • Remane Y; University Hospital of Leipzig, Leipzig , Germany.
  • Frontini R; University Hospital of Leipzig, Leipzig , Germany.
  • Byrne J; Development Dept., mibe GmbH Arzneimittel, 06796 Brehna, Germany.
  • Reinhardt R; Development Dept., mibe GmbH Arzneimittel, 06796 Brehna, Germany.
Article em En | MEDLINE | ID: mdl-25828728
ABSTRACT
A suspension comprising of the three antibiotic substances amphotericin B, colistin sulfate and tobramycin sulfate is often used in clinical practice for the selective decontamination of the digestive tract of patients in intensive care. Since no detailed procedures, specifications or stability data are available for manufacturing this suspension, there may be discrepancies regarding formulation and stability of suspensions prepared in different pharmacies. The aim of this work is to develop a standardized formulation and to determine its stability under defined storage conditions. This would help guarantee that all patients receive the same preparation, therefore ensuring similar efficacy and improved safety. The first step in this process is to develop the required analytical tools to measure the content and purity of the drug substances in this complex mixture. In this paper, the development and validation of these tools as well as the development of the drug suspension formulation is described. The formulation comprises of Ampho-Moronal(®)-Suspension (Dermapharm) and a buffered, preservated aqueous solution of colistin sulfate and tobramycin sulfate. Two simple, well established high-performance liquid chromatography (HPLC) methods in the European Pharmacopoeia (EP) for impurity profiling of the two active ingredients amphotericin B and colistin sulfate were combined with a newly developed sample extraction procedure for the suspension. Sufficient selectivity and stability-indicating power have been demonstrated. Additionally, a new robust routine method was developed to determine possible degradation products of tobramycin sulfate in the investigated suspension. The specificity, precision, accuracy and linearity of the analytical procedures were demonstrated. The recovery rate was in the range of 90-110%. The precision results for the calculated impurities showed variation coefficients of <10%. The calibration curves were found to be linear with correlation of greater than 0.9994 for all components. The results show the suitability of the methods for the quality control analysis of the suspension.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tobramicina / Anfotericina B / Cromatografia Líquida de Alta Pressão / Colistina Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: J Chromatogr B Analyt Technol Biomed Life Sci Assunto da revista: ENGENHARIA BIOMEDICA Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tobramicina / Anfotericina B / Cromatografia Líquida de Alta Pressão / Colistina Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: J Chromatogr B Analyt Technol Biomed Life Sci Assunto da revista: ENGENHARIA BIOMEDICA Ano de publicação: 2015 Tipo de documento: Article